Asciminib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 326 publications

A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.

A novel hyperactive BCR::ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy.

Journal: medRxiv : the preprint server for health sciences

Published: May 04, 2026

Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways.

Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways.

Journal: Future medicinal chemistry

Published: April 21, 2026

From Solid Organ Malignancies to Dual Leukaemias: Sequential CLL and CML in a Cancer Survivor.

From Solid Organ Malignancies to Dual Leukaemias: Sequential CLL and CML in a Cancer Survivor.

Journal: European journal of case reports in internal medicine

Published: April 20, 2026

Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia.

Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 15, 2026

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Journal: Cancers

Published: April 08, 2026

Response by Stepanian and Jaffe to Letters Regarding Article, "Ponatinib, but Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Response by Stepanian and Jaffe to Letters Regarding Article, "Ponatinib, but Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Journal: Circulation

Published: April 06, 2026

Letter by Liu and Li Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Letter by Liu and Li Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Journal: Circulation

Published: April 06, 2026

Letter by Zheng et al Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Letter by Zheng et al Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Journal: Circulation

Published: April 06, 2026

Letter by Xu et al Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Letter by Xu et al Regarding Article, "Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke".

Journal: Circulation

Published: April 06, 2026

Beyond ATP: asciminib and the allosteric path in CML.

Beyond ATP: asciminib and the allosteric path in CML.

Journal: Blood

Published: March 26, 2026

Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations.

Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations.

Journal: Expert opinion on pharmacotherapy

Published: March 24, 2026

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

Journal: Leukemia

Published: March 20, 2026

Showing 1-12 of 326

Last Updated: 06/30/2026